

SELARSDI (ustekinumab-aekn) **Order**

intake@sageinfusion.com sageinfusion.com

PATIENT INFOR	MATION				
Patient Name:		DOB:		Gender: □ M □ F	
Address:		City:	State:	ZIP:	
Phone:		Email:	Ht:	Wt:	
Please Attach:	☐ Insurance cards	☐ History & Physical	☐ Most recent labs	☐ Medication list	
□ NKDA □ Alle	rgies:				
PRESCRIBER IN	IFORMATION				
Ordering Provid	ler Name:				
Provider NPI:		Phor	ne:	Fax:	
Practice Address	s:	City:	St	ate: ZIP:	
REQUIRED INFO	ORMATION FOR EITH	IER LEQEMBI AND KISUNLA	4		
☐ Clinical/Progre	ss Notes, Labs, Tests sı	upporting primary diagnosis			
☐ TB status and o	date (please attach res	sults):			
MEDICATION C	ND FDC				
	is Codes: □ K50.00 C	hron's disease w/o complica		eancolitis w/o complications	
☐ New to Thera	py □ Continuatio	n of Therapy: Date of last d	lose (if applicable):		
PRE-MEDICATIO		.,			
	inophen1000mg PO ☐ Ceterizine 10r hydramine 25mg PO ☐ Solu-Medrol			☐ Solu-Cortef 100mg IVP☐ Diphenhydramine 25mg IVP	
DOSING/FREQUI	ENCY				
□Initial SELARS	DI Induction Infusio	n:			
Dilute in 250m Recommended	l 0.9% Sodium Chlorid I IV dosing based on v	le and administer intravenou veight (please choose one):	sly over 1 hour using 0.2 mi	cron filter tubing	
□ 260n □ 390n □ 520n	ng (2 vials) / up to 55 ng (3 vials) / greater tl ng (4 vials) / greater tl	kg nan 55 kg to 85 kg nan 85 kg			
☐ Initial Selarsd Dose: 90mg F	i Induction Infusion (requency: subcutaneo	(above) followed by Maintous injection at week 8 (after	enance Subcutaneous Inje initial infusion) and every 8	ctions: weeks thereafter	
☐Maintenance S Dose: 90mg Fr	Subcutaneous Injecti requency: subcutaneo	ons Only (no induction info us injection q 8 weeks	usion required)		
☐ Refills:					
Sage Infusion St	anding Orders:				
☑ Provide treatm	-	ion's Clinical Guidelines, Mec	dication Safety Protocol, Em	ergency Guidelines, and	
Provider Name		Provider Signature		te	